Resistance to imatinib, low-grade FDG-avidity on PET, and acquired KIT exon 17 mutation in gastrointestinal stromal tumour
- 1 September 2005
- journal article
- case report
- Published by Elsevier in The Lancet Oncology
- Vol. 6 (9), 724-727
- https://doi.org/10.1016/s1470-2045(05)70321-1
Abstract
No abstract availableThis publication has 14 references indexed in Scilit:
- Mechanisms of resistance to imatinib mesylate in gastrointestinal stromal tumors and activity of the PKC412 inhibitor against imatinib-resistant mutantsGastroenterology, 2005
- Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trialThe Lancet, 2004
- KIT Mutations Are Common in Testicular SeminomasThe American Journal of Pathology, 2004
- Kinase Mutations and Imatinib Response in Patients With Metastatic Gastrointestinal Stromal TumorJournal of Clinical Oncology, 2003
- Effect of tyrosine kinase inhibitor STI571 on the kinase activity of wild-type and various mutated c-kit receptors found in mast cell neoplasmsOncogene, 2003
- PDGFRA Activating Mutations in Gastrointestinal Stromal TumorsScience, 2003
- c‐kit Gene mutation at exon 17 or 13 is very rare in sporadic gastrointestinal stromal tumorsJournal of Gastroenterology and Hepatology, 2003
- Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or AmplificationScience, 2001
- Malignant Gastrointestinal Stromal Tumors of the Small Intestine: A Review of 50 Cases From a Prospective DatabaseAnnals of Surgical Oncology, 2001
- KIT Extracellular and Kinase Domain Mutations in Gastrointestinal Stromal TumorsThe American Journal of Pathology, 2000